Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
Shqipdona LahuGjin NdrepepaFranz-Josef NeumannMaurizio MenichelliIsabell BernlochnerGert RichardtJochen WöhrleBernhard WitzenbichlerRayyan HemetsbergerKatharina MayerIbrahim AkinSalvatore CasseseSenta GewaltErion XhepaSebastian KufnerChristian ValinaHendrik B SagerMichael JonerTareq IbrahimKarl-Ludwig LaugwitzHeribert SchunkertStefanie SchüpkeAdnan KastratiPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
In patients with ACS, pre-admission therapy with aspirin and/or clopidogrel has no influence on the relative efficacy and safety of ticagrelor and prasugrel.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- emergency department
- phase iii
- coronary artery disease
- clinical trial
- study protocol
- phase ii
- combination therapy
- cardiovascular disease
- randomized controlled trial
- type diabetes
- replacement therapy
- stem cells
- cardiovascular events
- smoking cessation